Released Aug 12, 2025, before the open
10-Q filed Aug 12, 2025, 43 days after period end · 0001576885-25-000093
Q2 2025 · 10-Q
Revenue—
Net Income-$40.95M-$40.95M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.68-$0.68 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$41,750,000N/M
Operating Cash Flowderived-$31,832,000N/M
Free Cash Flowderived-$31,841,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$40.95M | -$20.54M | -$11.61M | -$10.15M |
| EPS Diluted | -$0.68 | -$0.34 | -$0.28 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR